Targeted Toxins from Here to There (continued on page 6)

by Dr. Douglas Lappi

ATS visits U.S.S. Asheville

Targeting Teaser Winners

Recent Scientific References

• Winters BD, Bussey TJ (2005) Removal of cholinergic input to perirhinal cortex disrupts object recognition but not spatial working memory in the rat. Eur J Neurosci 21(8):2263-2270. (192-IgG-SAP, Cat. #IT-01)
• Duxbury MS, Ito H, Ashley SW, Whang EE (2004) CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma. Biochem Biophys Res Commun 317(3):837-843. (Streptavidin-ZAP, Cat. #IT-27)
• Gil-Bea FJ, Garcia-Alloza M, Dominguez J, Marcos B, Ramirez MJ (2005) Evaluation of cholinergic markers in Alzheimer’s disease and in a model of cholinergic deficit. Neurosci Lett 375(1):37-41. (192-IgG-SAP, Cat. #IT-01)
• Pappas BA, Payne KB, Fortin T, Sherren N (2005) Neonatal lesion of forebrain cholinergic neurons: Further characterization of behavioral effects and permanency. Neuroscience 133(2):485-492. (192-IgG-SAP, Cat. #IT-01)
• Scattoni ML, Puopolo M, Calamandrei G, Ricceri L (2005) Basal forebrain cholinergic lesions in 7-day-old rats alter ultrasound vocalisations and homing behaviour. Behav Brain Res 161(1):169-172. (192-IgG-SAP, Cat. #IT-01)

Recent Scientific References

• Smith HR, Pang KC (2005) Orexin-saporin lesions of the medial septum impair spatial memory. Neuroscience 132(2):261-271. (Orexin-SAP, Cat. #IT-20)
• Turchi J, Saunders RC, Mishkin M (2005) Effects of cholinergic deafferentation of the rhinal cortex on visual recognition memory in monkeys. Proc Natl Acad Sci U S A 102(6):2158-2161. (ME20.4-SAP, Cat. #IT-15)
• Paban V, Jaffard M, Chambon C, Malafosse M, Alescio-Lautier B (2005) Time course of behavioral changes following basal forebrain cholinergic damage in rats: Environmental enrichment as a therapeutic intervention. Neuroscience 132(1):13-32. (192-IgG-SAP, Cat. #IT-01)
• Wiley RG, Lappi DA (2005) Molecular Neurosurgery With Targeted Toxins. Humana Press Totowa, New Jersey. (see cover article for summary of this book, continued)

Targeting Talk: Saporin Safety

• You have stated previously in Targeting Trends that it was unlikely that saporin compounds or constituents would be excreted in urine or feces. However, you acknowledge that experimental data is lacking. Have there been any tests of animal urine or feces for saporin content? My animal care staff are concerned.
• Are there any studies which indicate what doses of saporin (by itself or compounded with an antibody) would be hazardous if ingested or injected (i.e. systemic dose level resulting in death or organ dysfunction).

Targeted Toxins from Here to There (continued from page 1)

Special Offer: Order $500 or more of ATS products during the month of July and receive a free copy of Molecular Neurosurgery With Targeted Toxins. (one book per customer, please)

SP-SAP Partnering Opportunity

More New Antibodies (GPCR Antibodies)

Targeting Tools: Featured Products

• New Antibodies: SSTr1 (Cat. #AB-N35), SSTr5 (Cat. #AB-N24), NK-1r (Cat. #AB-N33AP)

Targeting Teaser (Jumble)